Core Insights - Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high following positive results from an early test of its oral anti-inflammatory drug KT-621 [1][4] - The Phase 1b trial demonstrated significant reduction in inflammation for patients with eczema and asthma, targeting the STAT6 protein that influences immune responses [1][2] - CEO Nello Mainolfi highlighted that the results exceeded expectations and validated the company's STAT6 degrader program [2] Company Developments - A Phase 2b trial for KT-621 in eczema patients is currently underway, with expected results by mid-2027 [3] - A second Phase 2b trial for asthma patients is set to begin in the first quarter of next year [3] - Year-to-date, Kymera Therapeutics shares have increased approximately 140% [3]